Health Trials

PD-L1 Gene Mutation

3

Review clinical trials related to PD-L1 Gene Mutation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients

To evaluate the potential usefulness of 68Ga/18F-PD-L1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients

Participants needed: 500
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Tianjin Medical UniversityUpdated: Jun 1, 2026Locations: 2Duration: 7 Days
Eligibility criteria

(i) adult patients (aged 18 years or order); (ii) patients with suspected or new...

(i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the...

Read more
Status: Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.

Participants needed: 150
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Antalya Training and Research HospitalUpdated: Apr 30, 2026Locations: 25
Eligibility criteria

Signed informed consent form. [+4]

Patients who are not receiving atezolizumab for the treatment of lung cancer acc... [+2]

Read more
Status: Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

This study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1/PD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.

Participants needed: 200
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Wuxi People's HospitalUpdated: May 28, 2024Locations: 1
Eligibility criteria

Male or female aged 18-75 years; [+5]

The patient is diagnosed with central nervous system leukemia(symptoms, signs, i... [+10]

Read more